Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FGFR3
REST API REST API
Homo sapiens
FGFR3 is differentially expressed in 269 experiments: 197 organism parts: lung, amygdala, ... (195 more);, 195 disease states: normal, colorectal adenocarcinoma, ... (193 more);, 81 cell types 451 cell lines 27 compound treatments and 78 other conditions.
Synonyms CD333, JTK4, CEK2, ACH
Orthologs fgfr3 (Danio rerio)   FGFR3_CHICK (Gallus gallus)   Q95KL3_BOVIN (Bos taurus)   FGFR_CIOIN (Ciona intestinalis)   Fgfr3 (Rattus norvegicus)   Fgfr3 (Mus musculus)   htl (Drosophila melanogaster)   btl (Drosophila melanogaster)   fgfr3 (Xenopus laevis)   O62790_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term focal adhesion, plasma membrane, fibroblast growth factor binding, protein binding, morphogenesis of an epithelium, digestive tract morphogenesis, negative regulation of cell proliferation, negative regulation of smoothened signaling pathway, positive regulation of cell proliferation, lysosome, negative regulation of apoptosis, peptidyl-tyrosine phosphorylation, positive regulation of protein ubiquitination, MAPKKK cascade, protein tyrosine kinase activity, insulin receptor signaling pathway, positive regulation of apoptosis, fibroblast growth factor receptor signaling pathway, cell differentiation, ATP binding, transferase activity, transferring phosphorus-containing groups, integral to plasma membrane, response to axon injury, somatic stem cell maintenance, receptor activity, nucleotide binding, protein serine/threonine kinase activity, JAK-STAT cascade, perinuclear region of cytoplasm, integral to membrane, negative regulation of transcription from RNA polymerase II promoter, negative regulation of epithelial cell proliferation, protein kinase activity, regulation of apoptosis, negative regulation of mitosis, positive regulation of tyrosine phosphorylation of Stat1 protein, internal side of plasma membrane, bone morphogenesis, endochondral ossification, positive regulation of peptidyl-tyrosine phosphorylation, chondrocyte differentiation, lens morphogenesis in camera-type eye, positive regulation of ERK1 and ERK2 cascade, inner ear development, forebrain development, positive regulation of canonical Wnt receptor signaling pathway, positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway, lens fiber cell development, positive regulation of cell differentiation, cartilage development, positive regulation of phospholipase activity, cochlea development, skeletal system development, negative regulation of astrocyte differentiation, positive regulation of endothelial cell proliferation, oligodendrocyte development, positive regulation of MAPKKK cascade, inner ear receptor cell differentiation, positive regulation of tyrosine phosphorylation of Stat3 protein, protein autophosphorylation, protein phosphorylation, central nervous system myelination, negative regulation of developmental growth, axonogenesis involved in innervation, substantia nigra development, endochondral bone growth, alveolar secondary septum development, epithelial cell fate commitment, positive regulation of phosphatidylinositol 3-kinase activity, bone maturation, fibroblast growth factor-activated receptor activity, chondrocyte proliferation
InterPro Term Ig_sub, Immunoglobulin, Tyr_kinase_fibroblast_GF_rcpt, Prot_kinase_cat_dom, Ig-like, Ig_sub2, Ig_I-set, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q96T36, Q96T34, P22607, Q9NRB6, Q8NI16, Q8NI15, F8W9L4
Gene-Disease Assocation CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME, TESTICULAR TUMORS, BLADDER CANCER, MYELOMA, MULTIPLE, CERVICAL CANCER, KERATOSIS, SEBORRHEIC, NEVUS, EPIDERMAL, MUENKE SYNDROME, THANATOPHORIC DYSPLASIA, TYPE II; TD2, COLORECTAL CANCER; CRC, LACRIMOAURICULODENTODIGITAL SYNDROME; LADD, CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS; CAN, HYPOCHONDROPLASIA; HCH, ACHONDROPLASIA; ACH, THANATOPHORIC DYSPLASIA, TYPE I; TD1
Search EB-eye ENSG00000068078
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-2549, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
K562
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
445 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-MEXP-750, ... (41 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
plasma cell
2
E-MEXP-2360, E-GEOD-6691
1
2
E-TABM-130, E-TABM-145
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
stromal cell
1
2
E-MEXP-1327, E-GEOD-10797, E-GEOD-3998
germ cell
1
E-MTAB-25
75 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-8581, E-GEOD-2466, ... (42 experiments)

Factor Value U/D Experiments
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MEXP-66, E-MTAB-62
uterine fibroid
2
E-GEOD-2725, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-6631
prostate carcinoma
2
E-MTAB-37, E-MTAB-62
non-tumoral alcoholic non-cirrhotic liver
1
E-MTAB-62
189 more value(s).


Compound treatment

studied in E-GEOD-1802, E-GEOD-6907, E-TABM-782, E-GEOD-5824, E-GEOD-3720, ... (17 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-20719, E-TABM-782, E-GEOD-1802, E-GEOD-5824, E-GEOD-412, ... (6 experiments)
placebo
1
E-MEXP-1337
filtered air
1
E-TABM-127
glucose
1
E-MEXP-941
Cxcl12
1
1
E-GEOD-7307
NaOH
1
1
E-MEXP-2590
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-994, ... (11 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-147

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-20847, E-MTAB-108, E-GEOD-361, ... (7 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-3494, E-GEOD-2466, E-MEXP-421, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-GEOD-1926, E-MEXP-2069, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-6802, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-22541, E-GEOD-4922, E-TABM-147

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.394 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM